Financial

Shorter procedure times, fewer wound complications, reduced post-surgical care cost. All hot buttons for medtech investors, so it seems

New money should keep foot on accelerator with commercialisation efforts of new spinal technologies

Proving the lure of an innovative, FDA approved technology

XENiOS® receives cash infusion from existing investors to expand commercial operations in US and Europe

There’s a high degree of continuity built into St. Jude’s succession plan, Michael Rousseau having been around since 1999 and COO since last year

New financing will accelerate R&D and accelerate global sales and marketing capabilities

It looks like ReWalk is enduring that tricky period for any nascent device company, where sales grow, but expenses grow more

Further investment will support Moximed’s efforts to obtain FDA approval of its KineSpring System as well as accelerate its European commercialization

Recent acceleration of its clinical program suggests the spinal solutions company is back on track

U.S. sales growth more than compensates for currency-driven hit on OUS revenue

Another storm-weathering exercise sees GI Dynamics reverse-splitting its stock on a 1:10 basis as it attempts to shore up its ailing share price

Precision Spine, Inc. says it has finalized a major financial agreement that will enable the company to refinance its existing debt and pursue strategic acquisitions.

Preliminary revenue results for St. Jude’s fourth quarter see it expecting to report overall net sales growth with starring performances from Atrial Fibrillation

Achieving your guidance goals is one thing, and while the mood music is reassuring, there remains a big and expensive job to do.

It’s full steam ahead for Claret Medical as it announces Series B financing that will take it a long way down the road to US FDA approval, assuming its pivotal study goes to plan.

Volcano’s revenue guidance is well down on last quarter, although the company says it’s actions to reduce costs will mean the bottom line looks unchanged.